Safety and Efficacy of Topamax Versus Carbamazepine in Benign Rolandic Epilepsy

Epilepsy, Rolandic Clinical Trial

Official title:

A Randomized, Open Label, Comparative, Multi-center Clinical Trial to Determine the Efficacy and Safety of Topiramate Comparing With Carbamazepine in Benign Rolandic Epilepsy.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00216567
• Other study ID #: CR005077
• Status: Completed
• Phase: Phase 4
• First received: September 13, 2005
• Last updated: January 31, 2011
• Start date: December 2002
• Est. completion date: February 2006

Study information

• Verified date: January 2011
• Source: Janssen Korea, Ltd., Korea
• Contact: n/a
• Is FDA regulated: No
• Health authority: Korea: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the efficacy and safety of Topiramate in comparison to Carbamazepine in Benign rolandic epilepsy.

Description:

Benign rolandic epilepsy (BRE) is a common seizure disorder confined solely to children. The disorder is marked clinically by nocturnal generalized tonic-clonic seizures and diurnal seizures consisting of simple partial seizures consisting of brief unilateral facial clonic activity, dysphasia, and drooling. The EEG abnormalities are unique, consisting of generally high amplitude, centrotemporal spikes that are activated by sleep. The seizures typically begin in the first decade and almost always stop by age 16 years. The seizures are usually infrequent although clusters of seizures do occur. When the physician elects to treat, the seizures are usually easily controlled. This is a randomized, open label, active controlled, multi-center based clinical trial to determine the efficacy and safety of Topiramate comparing with Carbamazepine in Benign rolandic epilepsy. The study hypothesis is that topiramate will be more effective in treatment of Benign rolandic epilepsy than Carbamazepine, as evaluated by seizure-free rate at 24 weeks and Intellectual Functioning : KEDI-WISC (Korean Educational Development Institute Wechsler Intelligence Scale for Children-Revised) and is generally well-tolerated.

Topiramate (target dose) 4mg/kg/day, B.I.D, oral, for 24 weeks, carbamazepine(target dose) 30mg/kg/day, B.I.D, oral, for 24 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 114
• Est. completion date: February 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 5 Years to 15 Years

Eligibility

Inclusion Criteria:

• Subjects whose guardians submitted written consent

• Subjects with more than 2 seizures in last 1 year

• Subjects showing one of the following additional criteria

• Psychological burden due to seizure

• Seizure in daytime

• More than 3 seizures in last 6 month

• Convulsive seizure

Exclusion Criteria:

• Abnormalities on MRI, EEG

• Mental retardation

• History of seizure relapse

• Seizures due to organic causes

• Medically serious acute or chronic disease or progressive and degenerative disorders

• Patients who have received an investigational medication

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Epilepsy
• Epilepsy, Rolandic

Intervention

Drug:
• topamax

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Janssen Korea, Ltd., Korea

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Seizure-free rate at 24 weeks in comparison of topiramate to carbamazepine
Secondary	In comparison of topiramate to carbamazepine, Intellectual Functioning : KEDI-WISC (Korean Educational Development Institute Wechsler Intelligence Scale for Children-Revised)